NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines Corp (NASDAQ:BPMC) posted its earnings results on Tuesday, November, 5th. The biotechnology company reported ($1.93) earnings per share for the quarter, topping analysts' consensus estimates of ($2.19) by $0.26. The biotechnology company had revenue of $9.14 million for the quarter, compared to analyst estimates of $2.85 million. Blueprint Medicines had a negative return on equity of 77.27% and a negative net margin of 2,258.84%. The firm's revenue was up 734.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.66) EPS. View Blueprint Medicines' Earnings History.

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Blueprint Medicines.

11 equities research analysts have issued twelve-month price targets for Blueprint Medicines' shares. Their forecasts range from $70.00 to $125.00. On average, they anticipate Blueprint Medicines' stock price to reach $107.36 in the next twelve months. This suggests a possible upside of 63.7% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.

Headlines about BPMC stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Blueprint Medicines earned a news sentiment score of -4.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Blueprint Medicines.

Some companies that are related to Blueprint Medicines include GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Amarin (AMRN), Dr.Reddy's Laboratories (RDY) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Nektar Therapeutics (NKTR), STMicroelectronics (STM), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS), Xilinx (XLNX), Canopy Growth (CGC) and Codexis (CDXS).

(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines' stock is owned by many different of institutional and retail investors. Top institutional investors include Zeke Capital Advisors LLC (0.02%), Strs Ohio (0.01%), Assenagon Asset Management S.A. (0.01%), Steward Partners Investment Advisory LLC (0.00%), Nisa Investment Advisors LLC (0.00%) and Allworth Financial LP (0.00%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.

BPMC stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.

BPMC stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Zeke Capital Advisors LLC, Steward Partners Investment Advisory LLC, Allworth Financial LP and Nisa Investment Advisors LLC. View Insider Buying and Selling for Blueprint Medicines.

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BPMC stock can currently be purchased for approximately $65.58.

Blueprint Medicines has a market capitalization of $3.23 billion and generates $44.52 million in revenue each year. The biotechnology company earns $-236,640,000.00 in net income (profit) each year or ($5.39) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.View Additional Information About Blueprint Medicines.

The official website for Blueprint Medicines is http://www.blueprintmedicines.com/.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]